SBIR/STTR Research Award

Activin A antagonist for treatment of cancer-associated cachexia

Award identifier 426dc5dfc093d26e9fb08c57eb15c4e9369b81445c5755b429023c01dc720e08Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$225,000

Program and phase

SBIR · Phase I

Award year

2015

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
ABREOS BIOSCIENCES, INC.
Proposal award date
2015-09-25
Contract end date
2016-03-24
UEI
KM24BL6J7XG3
Solicitation number
PA14-071
Topic code
NCI

Research abstract

DESCRIPTION provided by applicant Cachexia is a major cause of suffering and death among patients with late stage cancers and the current treatment options are limited and ineffective We have identified a novel Activin A inhibitory protein Cryptic that can potentially eliminate the muscle wasting activity of Activin in cachexia Activin A has been previously validated as a target using other ligand traps such as the Activin receptors ActRIIA and ActRIIB but those molecules are promiscuous in binding to other TGF beta family ligands which leads to compromising side effects Cryptic exhibits a far more targeted activity towards Activins and therefore may be an ideal therapeutic for Activin mediated conditions Preliminary data with an Fc fusion Cryptic Fc has shown in vivo efficacy in an osteoporosis model system with both bone and muscle restorative effects observed The goal of this project is to test Cryptic Fc in a mouse model of cachexia Mice implanted with the C colon adenocarcinoma cell line which rapidly manifest cachexia will be used to evaluate both prevention as well as the reversal of cachexia In specific aim various Cryptic deletion constructs will be prepared and analyzed for Activin binding and pharmacokinetics to identify optimal candidates for development In specific aim qualified Cryptic Fc constructs will be tested in the mouse model If successful these studies will provide proof of concept for Cryptic Fc in the treatment of cachexia and pave the way for more thorough pre clinical development This project is a collaboration between Abreos Biosciences and Dr Martinez Hackert Assistant Professor at Michigan State University and the discoverer of Crypticandapos s Activin inhibiting functions Abreos has secured exclusive rights to develop Cryptic for this and other indications PUBLIC HEALTH RELEVANCE Cachexia also known as muscle wasting disease is a common and debilitating side effect of many types of cancer This project aims to develop a new treatment that can restore lost muscle for patients suffering from this disease

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

11 SBIR/STTR records share this UEI (2014–2019). Reported award amounts total $5,088,511. Reported amounts are not federal obligations.

Phases: Phase I, Phase II – Direct to Phase II, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.